The Clinton Health Access Initiative (CHAI) and the American Cancer Society (ACS) has joined hands to expand the cancer access partnership (CAP) to enhance access to lifesaving cancer treatments in low- and middle-income countries in Asia and Africa. Biocon Biologics Limited has also announced to join the growing list of companies in the CAP which currently includes Novartis, Pfizer, and Viatris.
This expanded partnership will make 26 medications in 39 formulations affordably available to low- and middle-income countries across Africa and Asia, such as key chemotherapies, hormonal therapies, biologics, and supportive therapies essential for the treatment of 30 cancers, including breast cancer.
The agreements will provide access to high quality trastuzumab, rituximab, and pegfilgrastim biosimilars in addition to previously available biosimilar filgrastim from Novartis. It also has the potential to generate an expected overall savings of 60 percent on purchased medications for governments, said an official release.
The new partnership between CHAI and ACS is made alongside the launch of the WHO’s new Global Breast Cancer Initiative which aims to bring together partners to reduce global breast cancer mortality by 2.5 percent per year, thereby averting 2.5 million breast cancer deaths globally between 2020 and 2040.
“This expanded partnership takes us another step closer to ensuring that the same cancer treatments are available to patients no matter where they live,” stated Dr Iain Barton, CEO of CHAI.
“Every person with cancer deserves affordable treatment that meets the high quality standards set by a stringent regulatory authority and these new agreements will make that possible for many people in Africa and Asia” said Dr Bill Cance, Chief Medical and Scientific Officer of the American Cancer Society.